EN-medication 2557 PDF

F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
tube feeding
Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
10-30
30
2 .
15-30
sustained release/enteric coated tablet
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
Reduce drug therapy to the minimum necessary.

Transfer the patient onto once-daily formulations with a
long half-life where possible (not modified-slow-release
formulations)
Determine alternative formulations and routes available
where possible
Make any therapy changes in an environment in which
the patient can be effectively monitored
www.themegallery.com
Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
drug absorption site

site of action
duration of action
Incompatibilities
antacid
opioids, tircyclic, betablocker, nitrate

bioavailability
intrajejunal
first pass metabolism
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
50
15-30
Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
10 - 30
immediate-release
Company Logo
10 30
10- 30
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
immediate-release
soft gelatin capsule

10 30 .
Clamp NG tube
GI
30
Company Logo
10- 30
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
sustained-release/ extended release dosage form

sublingual tablet
carcinogen
teratogen
cytotoxic
Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
, Practical Considerations in Administering Medication via Tube Feeding

Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic

Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic

Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic

Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic

Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
Bile acid sequestrant : Cholestyramine

(Questran)
semi-solid
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
Enteric coated tablet/pellet
pH 1-3
pH 3-5
pH 4.6-6
(duodenum)
enteric coat
pH > 5
pH 8 (jejunum)
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
NG tube
.d o
.c
m
o
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
.d o
lic
k
.c
m
o
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
Nexium MUPS
NG tube
syringe cap
NG tube
PEG tube
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
Theophylline
Theodur sustained release
200 mg, T1/2 12 hr, S = 1.0
Aminophylline prompt release

100 mg, T1/2 6-8 hr, S = 0.85
RX
Theodur200 mg q 12 hr via NG tube X X
(total theophylline 200mg/tab *2 tab =400 mg/day)
Aminophylline 100 mg q 6 hr via NG tube

(total theophylline 85mg/tab *4 tab =340 mg/day)
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
Dilantin
Diamicron
Nuelin SR
Adalat CR
lic
k
.d o
.c
sustained-release
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
Adalat CR
.d o
.c
m
o
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
Swallow whole
extended-release
tablet
Swallow as
crushed tablet
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
.d o
.c
m
o
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
EN
adsorb NG tube
phenytoin, diazepam
Dilantin kapseal
phenytoin sodium 100 mg
extended-release
Dilantin infatab
phenytoin 50 mg
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
Phenytoin serum level

control
Meat-based EN
Protein-hydrolysate EN
feeding
tube
West J Med 1989;150:659-66.
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
____1.
Atenolol+Actifed+Bromhexine
____2. KCl tab
____3.
____4.
____5. Dicloxacillin capsule
____6. Nifedipine 10 mg (
)
____7. Isordil 5 mg sublingual
____8.
____9.
30 ml
____10. Omeprazole capsule
Company Logo
20 ml
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c
F -X C h a n ge
F -X C h a n ge
c u -tr a c k
N
y
bu
to
k
lic
____11. Esomeprazole tablets (Nexium)

____12. CDR (
)
10-15 ml
____13.
Acetin powder(Fluimucil)100 mg
____14.
Phenytoin capsule SR 100 mg
Company Logo
.d o
.c
.d o
lic
to
bu
O
W
!
PD
O
W
!
PD
c u -tr a c k
.c

EN-medication 2557 PDF

Transféré par

Informations du document

Description originale:

Titre original

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

EN-medication 2557 PDF

Transféré par

Droits d'auteur :

Formats disponibles

F -X C h a n ge

Reduce drug therapy to the minimum necessary.

drug absorption site

opioids, tircyclic, betablocker, nitrate

soft gelatin capsule

sustained-release/ extended release dosage form

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

Bile acid sequestrant : Cholestyramine

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

Enteric coated tablet/pellet

Enteric coated tablet/pellet

Enteric coated tablet/pellet

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

, Practical Considerations in Administering Medication via Tube Feeding

200 mg, T1/2 12 hr, S = 1.0

Aminophylline prompt release

Aminophylline 100 mg q 6 hr via NG tube

Phenytoin serum level

West J Med 1989;150:659-66.

____11. Esomeprazole tablets (Nexium)

Vous aimerez peut-être aussi